Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Belrestotug - iTeos Therapeutics

Next Previous
Drug Profile

Belrestotug - iTeos Therapeutics

Alternative Names: EOS 884448; EOS-448; GSK-4428859; GSK-4428859A; TIGIT antagonist monoclonal antibody - iTeos Therapeutics

Latest Information Update: 30 May 2025

Price :
$50 *
Note:
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator iTeos Therapeutics
  • Developer GSK; iTeos Therapeutics
  • Class Antineoplastics; Immunotherapies; Monoclonal antibodies
  • Mechanism of Action Antibody-dependent cell cytotoxicity; T lymphocyte stimulants; TIGIT protein inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Phase III Non-small cell lung cancer
  • Phase II Squamous cell cancer
  • Phase I/II Haematological malignancies; Multiple myeloma; Solid tumours

Most Recent Events

  • 13 May 2025 GlaxoSmithKline discontinues a phase II trial in Squamous cell carcinoma of head and neck (Metastatic disease) in USA, Argentina, Brazil, Canada, Denmark, Finland, France, Germany, Greece, Hungary, Italy, Japan, South Korea, Norway, Poland, Portugal, Romania, Spain, Sweden, Taiwan and Turkey due to the results (NCT06062420)
  • 13 May 2025 iTeos Therapeutics in collaboration with GlaxoSmithKline terminated phase-II clinical trials in Non-small cell lung cancer (First-line therapy, Metastatic disease, Late-stage disease, Inoperable/Unresectable) inUS, Argentina, Belgium, Brazil, Finland, France, Germany, Greece, Hungary, Italy, Japan, South Korea, Netherlands, Poland, Portugal, South Africa, Spain, Thailand, United arab emirates, Mexico, Turkey and the United Kingdom (IV) due to disappointing results (NCT05565378)
  • 12 May 2025 iTeos Therapeutics terminates its licence for belrestotug with GSK

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top